JP2019527037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527037A5 JP2019527037A5 JP2018564409A JP2018564409A JP2019527037A5 JP 2019527037 A5 JP2019527037 A5 JP 2019527037A5 JP 2018564409 A JP2018564409 A JP 2018564409A JP 2018564409 A JP2018564409 A JP 2018564409A JP 2019527037 A5 JP2019527037 A5 JP 2019527037A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- smarca2
- level
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 63
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 claims 45
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 claims 45
- 230000014509 gene expression Effects 0.000 claims 39
- 239000003112 inhibitor Substances 0.000 claims 39
- 206010028980 Neoplasm Diseases 0.000 claims 36
- 239000003814 drug Substances 0.000 claims 35
- 201000011510 cancer Diseases 0.000 claims 34
- 230000011987 methylation Effects 0.000 claims 29
- 238000007069 methylation reaction Methods 0.000 claims 29
- 108090000623 proteins and genes Proteins 0.000 claims 27
- 102000004169 proteins and genes Human genes 0.000 claims 19
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 12
- 102100025746 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Human genes 0.000 claims 12
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 8
- 108700028341 SMARCB1 Proteins 0.000 claims 8
- 101150008214 SMARCB1 gene Proteins 0.000 claims 8
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 7
- 206010017758 gastric cancer Diseases 0.000 claims 7
- 201000011549 stomach cancer Diseases 0.000 claims 7
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 6
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 claims 6
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 102100037516 Protein polybromo-1 Human genes 0.000 claims 6
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 6
- 102100024793 SWI/SNF complex subunit SMARCC1 Human genes 0.000 claims 6
- 102100024790 SWI/SNF complex subunit SMARCC2 Human genes 0.000 claims 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 201000005292 ovarian small cell carcinoma Diseases 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 102100023157 AT-rich interactive domain-containing protein 2 Human genes 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 101000685261 Homo sapiens AT-rich interactive domain-containing protein 2 Proteins 0.000 claims 4
- 101000601770 Homo sapiens Protein polybromo-1 Proteins 0.000 claims 4
- 101000687718 Homo sapiens SWI/SNF complex subunit SMARCC1 Proteins 0.000 claims 4
- 101000687720 Homo sapiens SWI/SNF complex subunit SMARCC2 Proteins 0.000 claims 4
- 101000835860 Homo sapiens SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Proteins 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 108010047956 Nucleosomes Proteins 0.000 claims 4
- 208000036822 Small cell carcinoma of the ovary Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 210000001623 nucleosome Anatomy 0.000 claims 4
- 238000007634 remodeling Methods 0.000 claims 4
- 230000004043 responsiveness Effects 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 238000003364 immunohistochemistry Methods 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 claims 2
- LHGUZCKPFXXVPV-UHFFFAOYSA-N 1-[1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide Chemical compound C1CN(S(=O)(=O)CC)CCC1C(C)N1C2=CC=CC=C2C(C(=O)NCC=2C(NC(C)=CC=2OC)=O)=C1C LHGUZCKPFXXVPV-UHFFFAOYSA-N 0.000 claims 2
- ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]-4-indazolecarboxamide Chemical compound O=C1NC(C)=CC(C)=C1CNC(=O)C1=CC(C=2C=CC(CN3CCOCC3)=CC=2)=CC2=C1C=NN2C1CCCC1 ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 102100037151 Barrier-to-autointegration factor Human genes 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 238000001353 Chip-sequencing Methods 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- ULNXAWLQFZMIHX-UHFFFAOYSA-N GSK343 Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C=3C=NN(C=3C=C(C=2)C=2C=C(N=CC=2)N2CCN(C)CC2)C(C)C)=C1CCC ULNXAWLQFZMIHX-UHFFFAOYSA-N 0.000 claims 2
- 101000740067 Homo sapiens Barrier-to-autointegration factor Proteins 0.000 claims 2
- 101000584499 Homo sapiens Polycomb protein SUZ12 Proteins 0.000 claims 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 102100030702 Polycomb protein SUZ12 Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 101710136946 Protein polybromo-1 Proteins 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 101710169053 SWI/SNF complex subunit SMARCC1 Proteins 0.000 claims 2
- 101710169052 SWI/SNF complex subunit SMARCC2 Proteins 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000000121 hypercalcemic effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 210000002751 lymph Anatomy 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims 2
- HRDQQHUKUIKFHT-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-methyl-6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1-propan-2-ylindole-4-carboxamide Chemical compound C1=C2N(C(C)C)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCN(C)CC1 HRDQQHUKUIKFHT-UHFFFAOYSA-N 0.000 claims 2
- HPODOLXTMDHLLC-QGZVFWFLSA-N n-[(4-methoxy-6-methyl-2-oxo-1h-pyridin-3-yl)methyl]-2-methyl-1-[(1r)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]ethyl]indole-3-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C3=CC=CC=C3N([C@H](C)C3CCN(CC(F)(F)F)CC3)C=2C)=C1OC HPODOLXTMDHLLC-QGZVFWFLSA-N 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000002628 peritoneum cancer Diseases 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 150000003384 small molecules Chemical group 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 108010033040 Histones Proteins 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 238000003559 RNA-seq method Methods 0.000 claims 1
- 238000011529 RT qPCR Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000011223 gene expression profiling Methods 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 238000003196 serial analysis of gene expression Methods 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347436P | 2016-06-08 | 2016-06-08 | |
| US62/347,436 | 2016-06-08 | ||
| PCT/US2017/036515 WO2017214373A1 (en) | 2016-06-08 | 2017-06-08 | Diagnostic and therapeutic methods for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019527037A JP2019527037A (ja) | 2019-09-26 |
| JP2019527037A5 true JP2019527037A5 (enExample) | 2020-07-27 |
Family
ID=59325632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564409A Pending JP2019527037A (ja) | 2016-06-08 | 2017-06-08 | がんのための診断及び治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200129519A1 (enExample) |
| EP (1) | EP3469099A1 (enExample) |
| JP (1) | JP2019527037A (enExample) |
| CN (1) | CN109312407A (enExample) |
| WO (1) | WO2017214373A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| EP3576729A4 (en) * | 2017-02-02 | 2021-04-14 | Epizyme, Inc. | CANCER TREATMENT MODALITIES |
| AU2018227774A1 (en) * | 2017-02-28 | 2019-09-19 | Epizyme, Inc. | Inhibition of SMARCA2 for treatment of cancer |
| US20220154295A1 (en) * | 2019-03-27 | 2022-05-19 | The Johns Hopkins University | Methods and materials for assessing and treating cancer |
| CN111849866B (zh) * | 2020-07-15 | 2022-06-24 | 华南农业大学 | H3K27me3调控FoxO1基因表达在猪卵巢颗粒细胞中的应用 |
| CN112904006B (zh) * | 2021-01-28 | 2022-12-27 | 中山大学 | 一种乳腺癌预后预测分子标志物及其应用 |
| JP2023082308A (ja) * | 2021-12-02 | 2023-06-14 | 国立大学法人 長崎大学 | スクリーニング方法、環状ペプチドおよびこれを含む癌細胞増殖抑制剤 |
| DE102022112378B4 (de) * | 2022-05-17 | 2024-02-15 | Abberior Instruments Gmbh | Verfahren, lichtmikroskop und computerprogramm zur bestimmung eines referenzzeitpunktes |
| KR20240086713A (ko) * | 2022-11-22 | 2024-06-19 | 주식회사 네오나 | Gas5 억제제 및 smarca4 억제제를 유효성분으로 포함하는 간암 예방 또는 치료용 약학 조성물 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| ATE135373T1 (de) | 1989-09-08 | 1996-03-15 | Univ Johns Hopkins | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| MX9700535A (es) | 1994-07-21 | 1997-04-30 | Akzo Nobel Nv | Formulaciones de peroxido de cetona ciclico. |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| DK0836605T3 (da) | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| SK284073B6 (sk) | 1996-04-12 | 2004-09-08 | Warner-Lambert Company | Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| DK0980244T3 (da) | 1997-05-06 | 2003-09-29 | Wyeth Corp | Anvendelse af quinazoline forbindelser til behandling af polycystisk nyresygdom |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| CA2306155A1 (en) | 1997-11-06 | 1999-05-20 | Philip Frost | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| EP2694677A2 (en) * | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| MX376008B (es) * | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| WO2014176047A1 (en) * | 2013-04-25 | 2014-10-30 | Novartis Ag | Markers for ezh2 inhibitors |
| TW201718598A (zh) * | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| AU2016325643B2 (en) * | 2015-09-25 | 2022-07-21 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type |
| WO2017139404A1 (en) * | 2016-02-08 | 2017-08-17 | Epizyme, Inc. | Methods of treating cancer |
-
2017
- 2017-06-08 WO PCT/US2017/036515 patent/WO2017214373A1/en not_active Ceased
- 2017-06-08 CN CN201780035692.5A patent/CN109312407A/zh active Pending
- 2017-06-08 US US16/305,708 patent/US20200129519A1/en not_active Abandoned
- 2017-06-08 EP EP17739384.0A patent/EP3469099A1/en not_active Withdrawn
- 2017-06-08 JP JP2018564409A patent/JP2019527037A/ja active Pending
-
2021
- 2021-07-08 US US17/370,721 patent/US20210338684A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527037A5 (enExample) | ||
| Tan et al. | PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy | |
| Liu et al. | AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer | |
| Sun et al. | LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer | |
| CN109790582B (zh) | 基于c-maf状态的乳腺癌治疗性治疗 | |
| US10837966B2 (en) | Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses | |
| US9880171B2 (en) | iASPP phosphorylation and metastatic potential | |
| JP2018078911A5 (enExample) | ||
| JP2016105731A5 (enExample) | ||
| Zhao et al. | Ubiquitin D is an independent prognostic marker for survival in stage IIB–IIC colon cancer patients treated with 5‐fluoruracil‐based adjuvant chemotherapy | |
| Tsunedomi et al. | Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells | |
| Wang et al. | HMGB1-containing nucleosome mediates chemotherapy-induced metastasis of human lung cancer | |
| Yang et al. | The clinicopathological features of BRAF mutated papillary thyroid cancers in Chinese patients | |
| AU2021203352A1 (en) | A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof | |
| Szweda et al. | Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology | |
| Sakellakis et al. | Patterns of indolence in prostate cancer | |
| JP2015525881A (ja) | 乳癌における予測マーカーとしてのＥＲα／Ｓｒｃ／ＰＩ３Ｋ複合体の検出 | |
| JP7249044B2 (ja) | 腫瘍細胞の悪性化抑制剤及び抗腫瘍剤 | |
| TW202122584A (zh) | 預測癌症預後之方法及其應用 | |
| WO2014185528A1 (ja) | Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法 | |
| Nawab | The Pharmaceutical applications of next generation sequencing in oncology drug designing and development | |
| Baretti et al. | Precision cancer trials with immunomodulatory agents: personalizing histology agnostic approaches | |
| Deng et al. | NRF1 Predominantly Causes EZH2 Overexpression in Cancer Cells | |
| Novak | Stay or go? | |
| Ziprin et al. | 24. KRAS and BRAF mutations are rare in anal squamous cell carcinoma, justifying the use of EGFR targeted therapies |